Sustainable HIV treatment in Africa through viral-load-informed differentiated care

Nature

Volumn 528, Issue 7580, 2015, Pages S68-S76

  Phillips, Andrew ^a   Shroufi, Amir ^b   Vojnov, Lara ^c   Cohn, Jennifer ^b   Roberts, Teri ^b   Ellman, Tom ^b   Bonner, Kimberly ^b   Rousseau, Christine ^d   Garnett, Geoff ^d   Cambiano, Valentina ^a   Nakagawa, Fumiyo ^a   Ford, Deborah ^e   Bansi Matharu, Loveleen ^a   Miners, Alec ^f   Lundgren, Jens D ^g   Eaton, Jeffrey W ^h   Parkes Ratanshi, Rosalind ⁱ   Katz, Zachary ^c   Maman, David ^b   Ford, Nathan ^j   Vitoria, Marco ^j   Doherty, Meg ^k   Dowdy, David ^l   Nichols, Brooke ^f   Murtagh, Maurine ^c   Wareham, Meghan ^m   Palamountain, Kara M ⁿ   Chakanyuka Musanhu, Christine ^o   Stevens, Wendy ^p   Katzenstein, David ^q   Ciaranello, Andrea ^r   Barnabas, Ruanne ^s   Braithwaite, R Scott ^t   Bendavid, Eran ^u   Nathoo, Kusum J ^l   Van De Vijver, David ^v   Wilson, David P ^w   Holmes, Charles ^x   Bershteyn, Anna ^y   Walker, Simon ^z   Raizes, Elliot ^aa   Jani, Ilesh ^ab   Nelson, Lisa J ^f   Peeling, Rosanna ^f   Terris Prestholt, Fern ^ac   Murungu, Joseph ^ac   Mutasa Apollo, Tsitsi ^h   Hallett, Timothy B ^h   Revill, Paul ^y   more..

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b MÉDECINS SANS FRONTIÈRES   (Switzerland)

^c CLINTON HEALTH ACCESS INITIATIVE   (United States)

^d BILL AND MELINDA GATES FOUNDATION   (United States)

^e MRC CLINICAL TRIALS UNIT   (United Kingdom)

^f LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^g UNIVERSITY OF COPENHAGEN   (Denmark)

^h IMPERIAL COLLEGE LONDON   (United Kingdom)

ⁱ MAKERERE UNIVERSITY   (Uganda)

^j WORLD HEALTH ORGANIZATION   (Switzerland)

^k JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^l ERASMUS MEDICAL CENTER   (Netherlands)

^m NORTHWESTERN UNIVERSITY   (United States)

ⁿ WHO Regional Office for Africa   (Zimbabwe)

^o UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^p STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^q MASSACHUSETTS GENERAL HOSPITAL   (United States)

^r UNIVERSITY OF WASHINGTON   (United States)

^s NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^t STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^u UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^v UNIVERSITY OF NEW SOUTH WALES   (Australia)

^w CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA   (Zambia)

^x INSTITUTE FOR DISEASE MODELING   (United States)

^y UNIVERSITY OF YORK   (United Kingdom)

^z CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^aa MINISTRY OF HEALTH   (Mozambique)

^ab U S DEPARTMENT OF STATE   (United States)

^ac MINISTRY OF HEALTH AND CHILD CARE   (Zimbabwe)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; EFAVIRENZ; EMTRICITABINE; RITONAVIR; TENOFOVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

COST-BENEFIT ANALYSIS; DISEASE TREATMENT; DRUG; FEASIBILITY STUDY; HUMAN IMMUNODEFICIENCY VIRUS; PUBLIC HEALTH; SUSTAINABILITY; VIRAL DISEASE;

AFRICA SOUTH OF THE SAHARA; ANTIVIRAL THERAPY; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; COST EFFECTIVENESS ANALYSIS; DRIED BLOOD SPOT TESTING; DRUG COST; EMPIRICISM; FEASIBILITY STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOWEST INCOME GROUP; PATIENT MONITORING; POINT OF CARE TESTING; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TREATMENT FAILURE; VIRAL LOAD TESTING; VIRUS LOAD; ADOLESCENT; ADULT; AFRICA; AGED; COST BENEFIT ANALYSIS; DRUG EFFECTS; ECONOMICS; HIV INFECTIONS; MIDDLE AGED; PERSONALIZED MEDICINE; PROCEDURES; VIROLOGY; YOUNG ADULT;

SUB-SAHARAN AFRICA;

ADOLESCENT; ADULT; AFRICA; AGED; ANTI-HIV AGENTS; COST-BENEFIT ANALYSIS; HIV INFECTIONS; HUMANS; MIDDLE AGED; PRECISION MEDICINE; VIRAL LOAD; YOUNG ADULT;

EID: 84949217000     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature16046     Document Type: Article

References (91)

1. Siapka, M., Remme, M., Dayo Obure, C., Maier, C., Dehne, K. L. & Vassall A. Is there scope for cost savings and efficiency gains in HIV services? A systematic review of the evidence from low-and middle-income countries. Bull. World Health Organ. 92, 499-511 (2014)
2. Tagar, E. et al. Multi-country analysis of treatment costs for HIV/AIDS (MATCH): facility-level ART unit cost analysis in Ethiopia, Malawi, Rwanda, South Africa and Zambia. PLoS ONE 9, e108304 (2014)
3. Menzies, N. A. et al. The cost of providing comprehensive HIV treatment in PEPFAR-supported programs. AIDS 25, 1753-1760 (2011)
4. Ware, N. C. et al. Toward an understanding of disengagement from HIV treatment and care in sub-Saharan Africa: a qualitative study. PLoS Med. 10, e1001369 (2013)
5. World Health Organisation. Technical and Operational Considerations for Implementing HIV Viral Load Testing. Access to HIV diagnostics (WHO, 2014)
6. UNAIDS. Landmark HIV Diagnostic Access Program will Save $150m and Help Achieve New Global Goals on HIV http://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2014/september/20140925prviralload (UNAIDS, 2014)
7. Phillips, A. N., Pillay, D., Miners, A. H., Bennett, D. E, Gilks, C. F. & Lundgren, J. D. Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet 371, 1443-1451 (2008)
8. Estill, J. et al. Viral load monitoring of antiretroviral therapy, cohort viral load and HIV transmission in Southern Africa: a mathematical modelling analysis. AIDS 26, 1403-1413 (2012)
9. Braithwaite, R.S. et al. Alternative antiretroviral monitoring strategies for HIV-infected patients in east Africa: opportunities to save more lives? J. Intl AIDS Soc. 14, 38 (2011)
10. Kimmel, A.D. et al. Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness. J. Acquir. Immune Defic. Syndr. 54, 258-268 (2010)
11. Braithwaite, R. S. et al. How do different eligibility guidelines for antiretroviral therapy affect the cost-effectiveness of routine viral load testing in sub-Saharan Africa? AIDS 28 (Suppl 1), S73-S83 (2013)
12. Estill, J. et al. Monitoring of antiretroviral therapy programmes in Malawi, South Africa and Zambia: Mathematical Modelling Study. PLoS ONE 8, e57611.15 (2013)
13. Keebler, D. et al. Cost-effectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models. Lancet Glob. Health 2, e35-e43 (2013)
14. Bendavid, E. et al. Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis. Arch. Int. Med. 17, 168 (2008)
15. Hamers, R. L., Sawyer, A. W., Tuohy, M., Stevens, W.S., Rinke de Wit, T. F & Hill, A. M. Cost-effectiveness of laboratory monitoring for management of HIV treatment in sub-Saharan Africa: a model-based analysis. AIDS 26, 1663-1672 (2012)
16. Rutstein, S. E. et al. Dried blood spots for viral load monitoring in Malawi: feasible and effective. PLoS ONE 10, e0124748 (2015)
17. Andreotti, M. et al. Correlation between HIV-1 viral load quantification in plasma, dried blood spots, and dried plasma spots using the Roche COBAS Taqman assay. J. Clin. Virol. 47, 4-7 (2010)
18. Garrido, C. et al. Correlation between human immunodeficiency virus type 1 (HIV-1) RNA measurements obtained with dried blood spots and those obtained with plasma by use of Nuclisens EasyQ HIV-1 and Abbott RealTime HIV load tests. J. Clin. Microbiol. 47, 1031-1036 (2009)
19. Johannessen, A. et al. Dried blood spots perform well in viral load monitoring of patients who receive antiretroviral treatment in rural Tanzania. Clin. Infect. Dis. 49, 976-981 (2009)
20. Marconi, A. et al. Evaluation of the Abbott Real-Time HIV-1 quantitative assay with dried blood spot specimens. Clin. Microbiol. Infect. 15, 93-97 (2009)
21. Arredondo, M. et al. Comparison of HIV-1 RNA measurements using plasma and dried blood spots (DBS) in the Automated Abbott Real Time Viral Load Assay. J. Clin. Microbiol. 50, 569-572 (2011)
22. Pirillo MF-Pinson, P. et al. Quantification of HIV-RNA from dried blood spots using Siemens VERSANT HIV-1 RNA (kPCR) assay. J. Antimicrob. Chemother. 66, 2823-2826 (2011)
23. Ondoa, P. et al. Performance and logistical challenges of alternative HIV-1 virological monitoring options in a clinical setting of Harare, Zimbabwe. BioMed Res. Int. 2014, 102598 (2014)
24. Fajardo, E. et al. Prospective evaluation of diagnostic accuracy of dried blood spots from finger prick samples for determination of HIV-1 Load with the NucliSENS Easy-Q HIV-1 version 2.0 Assay in Malawi. J. Clinical Microbiol. 52, 1343-1351 (2014)
25. Smit, P. W. et al. Systematic review of the use of dried blood spots for monitoring HIV viral load and for early infant diagnosis. PLoS ONE 9, e86461 (2014)
26. Rutstein, E. et al. Measures of viral load using Abbott RealTime HIV-1 Assay on venousand fingerstick dried blood spots from provider-collected specimens in Malawian District Hospitals. J. Clin. Virol. 60, 392-398 (2014)
27. Mavedzenge, S. N. et al. Finger prick dried blood spots for HIV viral load measurement in field conditions in Zimbabwe. PloS ONE 10, e0126878 (2015)
28. UNITAID. HIV/AIDS Diagnostics Technology Landscape. Semi Annual Update. www. unitaid.org (UNITAID, 2015)
29. World Bank. Country and Lending Data http://data.worldbank.org/about/country-and-lending-groups#Sub-Saharan-Africa (World Bank, 2015)
30. Duncombe, C. et al. Reframing HIV care: putting people at the centre of antiretroviral delivery. Trop. Med. Int. Health 20, 430-447 (2015)
31. Roberts, T., Bygrave, H., Fajardo, E. & Ford, N. Challenges and opportunities for the implementation of virological testing in resource-limited settings. J. Int. AIDS Soc. 15, 17324 (2012)
32. Cambiano, V. et al. Transmission of drug resistant HIV and its potential impact on mortality and treatment outcomes in resource-limited settings. J. Infect. Dis. 207, S57-S62 (2013)
33. Cambiano, V. et al. Predicted levels of HIV drug resistance: potential impact of expanding diagnosis, retention, and eligibility criteria for antiretroviral therapy initiation. AIDS 28, S15-S23 (2014)
34. Phillips, A. N. et al. Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations beginning treatment: modelling study and economic analysis. Lancet HIV 1, e85-e93 (2014)
35. Cambiano, V. et al. Assessment of the potential impact and cost-effectiveness of self-testing for HIV in low-income countries. J. Infect. Dis. http://dx.doi.org/10.1093/ infdis/jiv040 (2015)
36. Phillips, A. N. et al. Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second-line regimens in resource-limited settings. AIDS 25, 843-850 (2011)
37. Madec, Y., Leroy, S., Rey-Cuille, M.-A., Huber. F & Calmy, A. Persistent difficulties in switching to second-line ART in sub-Saharan Africa -a systematic review and meta-analysis. PLoS ONE 8, e82724 (2013)
38. Fox, M. P. et al. Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa. J. Acquir. Immune Defic. Syndr. 60, 428-437 (2012)
39. Johnston, V., Fielding, K. L., Charalambous, S., Churchyard, G., Phillips, A. & Grant, A. D. Outcomes following virological failure and predictors of switching to second-line antiretroviral therapy in a South African treatment program. J. Acquir. Immune Defic. Syndr. 1, 370-380 (2012)
40. Parkin, N. Measurement of HIV-1 viral load for drug resistance surveillance using dried blood spots: literature review and modelling of contribution of DNA and RNA. AIDS Rev. 16, 160-171 (2014)
41. Claxton, K., Walker, S., Palmer, S. & Sculpher, M. Appropriate Perspectives for Health Care Decisions, Centre for Health Economics Research Paper 54 (Univ. York, 2010)
42. Woods, E., Revill, P., Sculpher, M. & Claxton, K. Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research. https://www.york. ac.uk/media/che/documents/papers/researchpapers/CHERP109-cost-effectiveness-threshold-LMICs.pdf (Univ. York, 2015)
43. Salomon, J. A. et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet 380, 2129-4310 (2012)
44. Hyle, E. P. et al. The clinical and economic impact of point-of-care CD4 testing in Mozambique and other resource-limited settings: a cost-effectiveness analysis. PLoS Med. 11, e1001725 (2014)
45. MSF. Untangling the Web of Antiretroviral Price Reductions http://www.msfaccess. org/content/untangling-web-antiretroviral-price-reductions (MSF, 2014)
46. Decroo, T. et al. Four-year retention and risk factors for attrition among members of community ART groups in Tete, Mozambique. Trop. Med. Int. Health. 19, 514-521 (2014)
47. Rasschaert, F. et al. Sustainability of a community-based anti-retroviral care delivery model -a qualitative research study in Tete, Mozambique. J. Int. AIDS Soc. 17, 18910 (2014)
48. DART Trial Team. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 375, 123-131 (2010)
49. MSF. ART Adherence Club Report and Toolkit http://www.msf.org/sites/msf.org/files/ cag-toolkit.pdf
50. MSF. Community ART Group Toolkit. How to Implement the CAG Model. Bringing Treatment Closer to Home and Empowering Patients http://samumsf.org/resources/ toolkit-cag/ (MSF, 2015)
51. Simons, S. et al. Ways to Reduce Costs and Improve Quality in Patient Monitoring: Barriers to Improvement, Buhera & Gutu District Experience, Zimbabwe. Consultation on Implementation Issues for Monitoring People on ART in Low-Income Settings in Sub-Saharan Africa (MSF, 2015)
52. Babigumira, J. B. et al. Cost-effectiveness of a pharmacy-only refill program in a large urban HIV/AIDS clinic in Uganda. PLoS ONE 6, e18193 (2011)
53. UNAIDS and MSF. Community Based ART Delivery (UNAIDS, 2015)
54. Grimsrud, A. et al. Implementation of community-based adherence clubs for stable antiretroviral therapy patients in Cape Town, South Africa. J. Int. AIDS Soc. 18, 19984 (2015)
55. MSF and UNAIDS. Closer to Home http://www.msfaccess.org/sites/default/files/ MSF-assets/HIV-AIDS/Docs/AIDS-report-ClosertoHome-ENG-2012.pdf (MSF, 2012)
56. Ledergerber, B. et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 364, 51-62 (2004)
57. Terris-Prestholt F. First-line antiretroviral therapy for HIV-infected children. AIDS 29, 1261-1262 (2015)
58. Mermin, J. et al. Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial. Br. Med. J. 343, d6792 (2011)
59. Kahn, J. G. et al. CD4 cell count and viral load monitoring in patients undergoing antiretroviral therapy in Uganda: cost effectivness study. Br. Med. J. 343, d6884 (2011)
60. DART Trial Team. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 375, 123-131 (2010)
61. Jourdain, G. et al. Switching HIV treatment in adults based on CD4 count versus viral load monitoring: a randomized, non-inferiority trial in Thailand. PLoS Med 10, e1001494 (2013)
62. Saag, M. et al. Cluster randomized trial of routine vs discretionary viral load monitoring among adults starting ART: Zambia. 19th Conf. Retroviruses and Opportunistic Infections (2012)
63. Laurent, C. et al. Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial. Lancet Infect. Dis. 11, 825-833 (2011)
64. Boyer, S. et al. Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis. Lancet Infect. Dis. 13, 577-586 (2013)
65. Fox, M. P. et al. Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa. J. Acquir. Immune Defic. Syndr. 60, 428-437 (2012)
66. Johnston, V., Fielding, K. L., Charalambous, S., Churchyard, G., Phillips, A. & Grant, A. D. Outcomes following virological failure and predictors of switching to second-line antiretroviral therapy in a South African treatment program. J. Acquir. Immune Defic. Syndr. 1, 370-380 (2012)
67. Parkin, N. Measurement of HIV-1 viral load for drug resistance surveillance using dried blood spots: literature review and modelling of contribution of DNA and RNA. AIDS Rev. 16, 160-171 (2014)
68. Claxton, K., Walker, S., Palmer, S. & Sculpher, M. Appropriate Perspectives for Health Care Decisions, Centre for Health Economics Research Paper 54 (Univ. York, 2010)
69. Woods, E., Revill, P., Sculpher, M. & Claxton, K. Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research. https://www.york. ac.uk/media/che/documents/papers/researchpapers/CHERP109-cost-effectiveness-threshold-LMICs.pdf (Univ. York, 2015)
70. Salomon, J. A. et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet 380, 2129-4310 (2012)
71. Hyle, E. P. et al. The clinical and economic impact of point-of-care CD4 testing in Mozambique and other resource-limited settings: a cost-effectiveness analysis. PLoS Med. 11, e1001725 (2014)
72. MSF. Untangling the Web of Antiretroviral Price Reductions http://www.msfaccess. org/content/untangling-web-antiretroviral-price-reductions (MSF, 2014)
73. Decroo, T. et al. Four-year retention and risk factors for attrition among members of community ART groups in Tete, Mozambique. Trop. Med. Int. Health. 19, 514-521 (2014)
74. Rasschaert, F. et al. Sustainability of a community-based anti-retroviral care delivery model -a qualitative research study in Tete, Mozambique. J. Int. AIDS Soc. 17, 18910 (2014)
75. DART Trial Team. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 375, 123-131 (2010)
76. MSF. ART Adherence Club Report and Toolkit http://www.msf.org/sites/msf.org/files/ cag-toolkit.pdf
77. MSF. Community ART Group Toolkit. How to Implement the CAG Model. Bringing Treatment Closer to Home and Empowering Patients http://samumsf.org/resources/ toolkit-cag/ (MSF, 2015)
78. Simons, S. et al. Ways to Reduce Costs and Improve Quality in Patient Monitoring: Barriers to Improvement, Buhera & Gutu District Experience, Zimbabwe. Consultation on Implementation Issues for Monitoring People on ART in Low-Income Settings in Sub-Saharan Africa (MSF, 2015)
79. Babigumira, J. B. et al. Cost-effectiveness of a pharmacy-only refill program in a large urban HIV/AIDS clinic in Uganda. PLoS ONE 6, e18193 (2011)
80. UNAIDS and MSF. Community Based ART Delivery (UNAIDS, 2015)
81. Grimsrud, A. et al. Implementation of community-based adherence clubs for stable antiretroviral therapy patients in Cape Town, South Africa. J. Int. AIDS Soc. 18, 19984 (2015)
82. MSF and UNAIDS. Closer to Home http://www.msfaccess.org/sites/default/files/ MSF-assets/HIV-AIDS/Docs/AIDS-report-ClosertoHome-ENG-2012.pdf (MSF, 2012)
83. Ledergerber, B. et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 364, 51-62 (2004)
84. Terris-Prestholt F. First-line antiretroviral therapy for HIV-infected children. AIDS 29, 1261-1262 (2015)
85. Mermin, J. et al. Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial. Br. Med. J. 343, d6792 (2011)
86. Kahn, J. G. et al. CD4 cell count and viral load monitoring in patients undergoing antiretroviral therapy in Uganda: cost effectivness study. Br. Med. J. 343, d6884 (2011)
87. DART Trial Team. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 375, 123-131 (2010)
88. Jourdain, G. et al. Switching HIV treatment in adults based on CD4 count versus viral load monitoring: a randomized, non-inferiority trial in Thailand. PLoS Med 10, e1001494 (2013)
89. Saag, M. et al. Cluster randomized trial of routine vs discretionary viral load monitoring among adults starting ART: Zambia. 19th Conf. Retroviruses and Opportunistic Infections (2012)
90. Laurent, C. et al. Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial. Lancet Infect. Dis. 11, 825-833 (2011)
91. Boyer, S. et al. Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis. Lancet Infect. Dis. 13, 577-586 (2013)